Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL2931430

Clc1cccc(Cc2ccc(CN3CCOCC3)cc2)c1.N

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.58
HRH3 Q9Y5N1 2/20 0.54
PDE4B Q07343 2/20 0.54
NCF1 P14598 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.53
HTT P42858 3/20 0.52
RECQL P46063 1/20 0.52
CYP2A13 Q16696 2/20 0.50
LTA4H P09960 1/20 0.50
ALDH1A1 P00352 3/20 0.49
HPGD P15428 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
MEN1 O00255 1/20 0.49
PRKD3 O94806 1/20 0.49
KMT2A Q03164 1/20 0.49
PRKD1 Q15139 1/20 0.49
PRKD2 Q9BZL6 1/20 0.49
KDM4E B2RXH2 2/20 0.49
NOS1 P29475 1/20 0.49
GLA P06280 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4115394 0.89 SIGMAR1 (0.72) SIGMAR1HRH3PDE4BNCF1SMN1; SMN2
Ammonia Solution, Strong SCHEMBL2923323 0.89 CYP2A13 (0.68) SIGMAR1HRH3PDE4BNCF1SMN1; SMN2
Ammonia Solution, Strong SCHEMBL2926473 0.86 LTA4H (0.64) SIGMAR1HRH3SMN1; SMN2HTTLTA4H
Ammonia Solution, Strong SCHEMBL2930007 0.77 SIGMAR1 (0.57) SIGMAR1SMN1; SMN2CYP2A13LTA4HALDH1A1
SCHEMBL11196105 0.77 NCF1 (0.83) HRH3NCF1SMN1; SMN2HTTCYP2A13
4-(4-Chlorobenzyl)Morpholine SCHEMBL4103722 0.77 HRH3 (0.74) SIGMAR1HRH3SMN1; SMN2CYP2A13ALDH1A1
SCHEMBL15467001 0.77 HRH3 (0.87) HRH3NCF1SMN1; SMN2CYP2A13ALDH1A1
SCHEMBL2931427 0.76 HIF1A (0.61) HRH3PDE4BSMN1; SMN2ALDH1A1HPGD
SCHEMBL2928330 0.75 SMN1; SMN2 (0.64) HRH3PDE4BSMN1; SMN2ALDH1A1HPGD
SCHEMBL2931423 0.75 PDE4B (0.50) SIGMAR1HRH3PDE4BNCF1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2121616-B1 NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS CAMPIANI GIUSEPPE (IT) 2010-09-15 EP disclosed
US-20100093726-A1 NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS GIUSEPPE CAMPIANI (IT) 2010-04-15 US disclosed
EP-2121616-A1 NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS Campiani, Giuseppe (IT) 2009-11-25 EP disclosed
WO-2008101891-A1 NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS CAMPIANI GIUSEPPE (IT) 2008-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093726-A1 NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS QTRT1, QTRT2, IL4I1 SIGMAR1 2671/4885HRH3 30/4885PDE4B 556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.